MGMT and glioblastoma: In 2005, Hegi et al. [6] demonstrated in a post hoc analysis of a study cohort from a phase III study that glioblastoma patients aged 18 – 70 years with intratumoral MGMT gene silencing by promoter hypermethylation had significantly better outcomes when treated with combined radiochemotherapy with temozolomide as compared to patients treated with radiotherapy alone.